Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors
Abstract Background Little is known regarding associations between peripheral blood biomarkers (PBBMs) and survival, response, and toxicity in recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs). Methods In this single‐institution...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5697 |
| _version_ | 1797831076309106688 |
|---|---|
| author | Cassie Pan Qian Vicky Wu Jenna Voutsinas Jeffrey J. Houlton Brittany Barber Zain H. Rizvi Emily Marchiano Neal Futran George E. Laramore Jay J. Liao Upendra Parvathaneni Renato G. Martins Jonathan R. Fromm Cristina P. Rodriguez |
| author_facet | Cassie Pan Qian Vicky Wu Jenna Voutsinas Jeffrey J. Houlton Brittany Barber Zain H. Rizvi Emily Marchiano Neal Futran George E. Laramore Jay J. Liao Upendra Parvathaneni Renato G. Martins Jonathan R. Fromm Cristina P. Rodriguez |
| author_sort | Cassie Pan |
| collection | DOAJ |
| description | Abstract Background Little is known regarding associations between peripheral blood biomarkers (PBBMs) and survival, response, and toxicity in recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs). Methods In this single‐institution retrospective cohort study, a dataset of patients with R/M HNSCC treated with ICIs between 08/2012–03/2021 was established, including demographic and clinicopathologic characteristics. Pretreatment PBBMs were collected and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv5, objective response (ORR) by RECIST 1.1, overall survival (OS), and progression‐free survival (PFS). Multivariable models for each outcome were created using elastic net variable selection. Results Our study included 186 patients, with 51 (27%) demonstrating complete or partial response to immunotherapy. Multivariable models adjusted for ECOG performance status (PS), p16, and smoking demonstrated that pretreatment higher LDH and absolute neutrophils, as well as lower percent lymphocytes correlated with worse OS and PFS. Higher LDH and lower % lymphocytes also correlated with worse ORR. Conclusions In the largest study to date examining PBBMs in ICI‐treated R/M HNSCCs, our variable selection method revealed PBBMs prognostic for survival and response to immunotherapy. These biomarkers warrant further investigation in a prospective study along with validation with CPS biomarker. |
| first_indexed | 2024-04-09T13:46:15Z |
| format | Article |
| id | doaj.art-abf9f7ebd9ed41ab997ecff27e40bfec |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T13:46:15Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-abf9f7ebd9ed41ab997ecff27e40bfec2023-05-09T04:04:18ZengWileyCancer Medicine2045-76342023-04-011289384939110.1002/cam4.5697Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitorsCassie Pan0Qian Vicky Wu1Jenna Voutsinas2Jeffrey J. Houlton3Brittany Barber4Zain H. Rizvi5Emily Marchiano6Neal Futran7George E. Laramore8Jay J. Liao9Upendra Parvathaneni10Renato G. Martins11Jonathan R. Fromm12Cristina P. Rodriguez13Department of Otolaryngology‐Head and Neck Surgery University of Washington Seattle Washington USAClinical Research Division Fred Hutchinson Cancer Center Seattle Washington USAClinical Research Division Fred Hutchinson Cancer Center Seattle Washington USAHead & Neck Specialists Charleston South CarolinaDepartment of Otolaryngology‐Head and Neck Surgery University of Washington Seattle Washington USADepartment of Otolaryngology‐Head and Neck Surgery University of Washington Seattle Washington USADepartment of Otolaryngology‐Head and Neck Surgery University of Washington Seattle Washington USADepartment of Otolaryngology‐Head and Neck Surgery University of Washington Seattle Washington USADepartment of Radiation Oncology University of Washington Seattle Washington USADepartment of Radiation Oncology University of Washington Seattle Washington USADepartment of Radiation Oncology University of Washington Seattle Washington USADivision of Hematology, Oncology and Palliative Care Department of Medicine Virginia Commonwealth University Richmond Virginia USADepartment of Laboratory Medicine and Pathology University of Washington Seattle Washington USADivision of Oncology, Department of Medicine University of Washington Seattle Washington USAAbstract Background Little is known regarding associations between peripheral blood biomarkers (PBBMs) and survival, response, and toxicity in recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs). Methods In this single‐institution retrospective cohort study, a dataset of patients with R/M HNSCC treated with ICIs between 08/2012–03/2021 was established, including demographic and clinicopathologic characteristics. Pretreatment PBBMs were collected and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv5, objective response (ORR) by RECIST 1.1, overall survival (OS), and progression‐free survival (PFS). Multivariable models for each outcome were created using elastic net variable selection. Results Our study included 186 patients, with 51 (27%) demonstrating complete or partial response to immunotherapy. Multivariable models adjusted for ECOG performance status (PS), p16, and smoking demonstrated that pretreatment higher LDH and absolute neutrophils, as well as lower percent lymphocytes correlated with worse OS and PFS. Higher LDH and lower % lymphocytes also correlated with worse ORR. Conclusions In the largest study to date examining PBBMs in ICI‐treated R/M HNSCCs, our variable selection method revealed PBBMs prognostic for survival and response to immunotherapy. These biomarkers warrant further investigation in a prospective study along with validation with CPS biomarker.https://doi.org/10.1002/cam4.5697biomarkerscheck point controlhead and neck cancermedical oncologyprognostic factor |
| spellingShingle | Cassie Pan Qian Vicky Wu Jenna Voutsinas Jeffrey J. Houlton Brittany Barber Zain H. Rizvi Emily Marchiano Neal Futran George E. Laramore Jay J. Liao Upendra Parvathaneni Renato G. Martins Jonathan R. Fromm Cristina P. Rodriguez Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors Cancer Medicine biomarkers check point control head and neck cancer medical oncology prognostic factor |
| title | Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors |
| title_full | Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors |
| title_fullStr | Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors |
| title_full_unstemmed | Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors |
| title_short | Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors |
| title_sort | peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors |
| topic | biomarkers check point control head and neck cancer medical oncology prognostic factor |
| url | https://doi.org/10.1002/cam4.5697 |
| work_keys_str_mv | AT cassiepan peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT qianvickywu peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT jennavoutsinas peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT jeffreyjhoulton peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT brittanybarber peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT zainhrizvi peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT emilymarchiano peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT nealfutran peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT georgeelaramore peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT jayjliao peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT upendraparvathaneni peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT renatogmartins peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT jonathanrfromm peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors AT cristinaprodriguez peripherallymphocytesandlactatedehydrogenasecorrelatewithresponseandsurvivalinheadandneckcancerstreatedwithimmunecheckpointinhibitors |